- Home
- AVTX vs PMVP Comparison
AVTX vs PMVP Comparison
Compare AVTX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- PMVP
- Stock Information
- Founded
- AVTX 2011
- PMVP 2013
- Country
- AVTX United States
- PMVP United States
- Employees
- AVTX N/A
- PMVP N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- AVTX Health Care
- PMVP Health Care
- Exchange
- AVTX Nasdaq
- PMVP Nasdaq
- Market Cap
- AVTX 138.8M
- PMVP 77.4M
- IPO Year
- AVTX 2015
- PMVP 2020
- Fundamental
- Price
- AVTX $11.33
- PMVP $1.25
- Analyst Decision
- AVTX Strong Buy
- PMVP Strong Buy
- Analyst Count
- AVTX 9
- PMVP 1
- Target Price
- AVTX $30.14
- PMVP $5.00
- AVG Volume (30 Days)
- AVTX 188.1K
- PMVP 2.7M
- Earning Date
- AVTX 11-06-2025
- PMVP 11-06-2025
- Dividend Yield
- AVTX N/A
- PMVP N/A
- EPS Growth
- AVTX N/A
- PMVP N/A
- EPS
- AVTX N/A
- PMVP N/A
- Revenue
- AVTX $441,000.00
- PMVP N/A
- Revenue This Year
- AVTX N/A
- PMVP N/A
- Revenue Next Year
- AVTX N/A
- PMVP N/A
- P/E Ratio
- AVTX N/A
- PMVP N/A
- Revenue Growth
- AVTX N/A
- PMVP N/A
- 52 Week Low
- AVTX $3.39
- PMVP $0.81
- 52 Week High
- AVTX $16.00
- PMVP $1.84
- Technical
- Relative Strength Index (RSI)
- AVTX 62.61
- PMVP 43.37
- Support Level
- AVTX $9.54
- PMVP $1.12
- Resistance Level
- AVTX $12.41
- PMVP $1.40
- Average True Range (ATR)
- AVTX 1.05
- PMVP 0.16
- MACD
- AVTX -0.10
- PMVP -0.03
- Stochastic Oscillator
- AVTX 71.28
- PMVP 17.94
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.